Physician profile
Jerilyn Bautista Mendoza
NPI 1720860224
$8,287.49
in general payments reported to CMS, 2019-2025
55 companies · $3,884 in 2025
The $3,884 reported for 2025 was more than what 90% of Oncology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $57.05 · 2024: $4,222 · 2025: $3,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,685 · Education: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,684.50 |
| Education | $477.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $637.74 | 2024-2025 | |
| Janssen Biotech, INC. | $613.21 | 2024-2025 | Rybrevant, Carvykti, Darzalex |
| Merck Sharp & Dohme LLC | $589.82 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals Lp | $538.32 | 2024-2025 | Imfinzi, Lynparza, Calquence |
| Pfizer INC. | $378.28 | 2024-2025 | |
| Incyte Corporation | $325.46 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Exelixis INC. | $320.69 | 2024-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $318.78 | 2024-2025 | |
| Genmab U.S., INC. | $286.77 | 2023-2025 | Tivdak, Epkinly |
| Ipsen Biopharmaceuticals, INC | $264.05 | 2024-2025 | Onivyde, Tazverik |
| E.R. Squibb & Sons, L.L.C. | $252.58 | 2022-2025 | Opdivo, Opdualag |
| Eisai INC. | $215.58 | 2024-2025 | |
| Daiichi Sankyo INC. | $214.85 | 2024-2025 | Enhertu, Injectafer, Datroway |
| Glaxosmithkline, LLC. | $207.20 | 2024-2025 | Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $205.04 | 2024-2025 | Iclusig, Fruzaqla, Vpriv |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $186.56 | 2024-2025 | Libtayo, Lynozyfic |
| Genentech USA, INC. | $178.19 | 2024-2025 | Phesgo, Perjeta, Polivy |
| Astellas Pharma US INC | $173.28 | 2024-2025 | Vyloy |
| Celgene Corporation | $171.89 | 2024-2025 | Reblozyl, Opdivo |
| Lilly USA, LLC | $157.91 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Beigene USA, INC. | $127.90 | 2024-2025 | Tevimbra, Brukinsa |
| Abbvie INC. | $113.71 | 2024-2025 | |
| Kite Pharma, INC. | $112.47 | 2024-2025 | Yescarta |
| Emd Serono, INC. | $110.89 | 2024-2025 | |
| Array Biopharma INC | $107.54 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Sumitomo Pharma America, INC. | $101.59 | 2024-2025 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $97.21 | 2024 | Ultomiris |
| Tersera Therapeutics LLC | $87.65 | 2024-2025 | Xermelo, Zoladex |
| Bayer Healthcare Pharmaceuticals INC. | $77.78 | 2025 | |
| Agios Pharmaceuticals, INC. | $74.49 | 2025 | Pyrukynd |
| Iovance Biotherapeutics, INC. | $74.28 | 2025 | Amtagvi |
| Springworks Therapeutics, INC. | $68.34 | 2024-2025 | Ogsiveo |
| Immunocore Limited | $66.84 | 2024 | Kimmtrak |
| Taiho Oncology, INC. | $59.32 | 2025 | |
| Syndax Pharmaceuticals, INC. | $58.21 | 2025 | |
| Rigel Pharmaceuticals, INC. | $57.67 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Mirati Therapeutics, INC. | $53.88 | 2024 | Krazati |
| Sun Pharmaceutical Industries INC. | $52.02 | 2025 | |
| Karyopharm Therapeutics INC. | $50.25 | 2024 | Xpovio |
| Tempus Ai, INC | $46.93 | 2024 | |
| Azurity Pharmaceuticals, INC. | $46.73 | 2024-2025 | Danziten, Vivimusta |
| Legend Biotech USA INC. | $46.57 | 2024 | |
| Novocure INC. | $44.28 | 2025 | Optune Lua (Novottf-200t), Optune Gio |
| Puma Biotechnology, INC. | $41.68 | 2025 | |
| Stemline Therapeutics INC. | $35.20 | 2024-2025 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.05 | 2025 | |
| Acrotech Biopharma INC. | $32.32 | 2024 | Ryzneuta |
| Beone Medicines USA, INC. | $29.87 | 2025 | Tevimbra |
| Amneal Pharmaceuticals LLC | $28.80 | 2025 | Alymsys |
| Servier Pharmaceuticals LLC | $24.97 | 2024 | |
| Deciphera Pharmaceuticals INC. | $22.89 | 2024 | Qinlock |
| Pharmacosmos Therapeutics INC. | $20.78 | 2024 | Monoferric |
| Fresenius Kabi USA, LLC | $16.32 | 2024 | Stimufend |
| Coherus Oncology, INC. | $15.59 | 2023 | |
| Jazz Pharmaceuticals INC. | $13.27 | 2023 | Zepzelca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerilyn Mendoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.